Accessibility Menu
BIOINVENT AB logo

BIOINVENT AB(OTC) BOVNF

This security has been delisted. This page is retained for historical reference.

BIOINVENT AB last closing stock price
MetricPriceDate
Last closeUSD 3.292026-07-13
BIOINVENT AB stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 3.292025-06-10
1 month+0%USD 3.292025-06-10
3 month+0%USD 3.292025-06-10
Year to date+0%USD 3.292025-06-10
1 year+0%USD 3.292025-06-10
3 year-30.03%USD 4.702023-02-08
5 year-51.92%USD 6.842021-06-29
Since inception-29.28%USD 4.652008-06-19

BOVNF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

BOVNF Financials

Key Financial Metrics (TTM)

Gross Margin

98.48%

Operating Margin

-161.05%

Net Income Margin

-153.98%

Return on Equity

-53.88%

Return on Capital

-61.94%

Return on Assets

-62.71%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

SEK 214.54M

Operating Income

-SEK 349.68M

EBITDA

-SEK 324.89M

Operating Cash Flow

-SEK 319.11M

Capital Expenditure

-SEK 5.29M

Free Cash Flow

-SEK 264.65M

Cash & ST Invst.

SEK 456.48M

Total Debt

SEK 6.26M

BIOINVENT AB Performance Analysis

BIOINVENT AB annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 32,226,2291327.2%
20232023-12-31SEK 6,731,479-79.1%
20242024-12-31SEK 4,226,533-37.2%
20252025-12-31SEK 23,094,040446.4%
BIOINVENT AB sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30798.0%
Q32025-09-30-98.3%
Q42025-12-31-8.8%
Q12026-03-31346.2%
BIOINVENT AB annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -0.07-88.6%
20232023-12-31SEK -0.47592.7%
20242024-12-31SEK -0.6230.5%
20252025-12-31SEK -0.52-16.4%
BIOINVENT AB sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30133.3%
Q32025-09-30-433.9%
Q42025-12-312.5%
Q12026-03-315.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

SEK 13.42M

-39.2%

Gross Profit

SEK 13.42M

-39.2%

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

114

N/A

Net Income

-SEK 119.22M

-2.2%

EBITDA

-SEK 116.90M

+0.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

SEK 456.48M

-38.5%

Total Debt

SEK 6.26M

-58.8%

Accounts Receivable

SEK 37.75M

-45.5%

Inventory

SEK 11.48M

+49.1%

Long Term Debt

SEK 733.00K

-87.8%

Short Term Debt

SEK 11.03M

+20.3%

Return on Assets

-62.71%

N/A

Return on Invested Capital

-79.77%

N/A

Free Cash Flow

-SEK 133.45M

-8.7%

Operating Cash Flow

-SEK 132.81M

-10.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTCHFPureTech Health plc
$1.60+0.00%
NWBONorthwest Biotherapeutics, Inc.
$0.17+0.53%
CYDYCytoDyn Inc.
$0.20-6.54%
GSGTFGenSight Biologics S.A.
$0.09+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
TAT&T
$24.13+0.05%
AALAmerican Airlines Group
$14.48+0.07%
CLFCleveland-Cliffs
$11.93+0.09%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.